Apex Biotechnology (TPE:1733) Cyclically Adjusted Revenue per Share: NT$22.14 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1733 Apex Biotechnology Corp TPE:1733
80 GF Score
Price NT$32.05
GF Value NT$30.01
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Apex Biotechnology Cyclically Adjusted Revenue per Share?

Apex Biotechnology TPE:1733 +1.26% 80 Cyclically Adjusted Revenue per Share is NT$22.14 as of Dec. 2025. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$30.01 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Apex Biotechnology's adjusted revenue per share for the three months ended in Dec. 2025 was NT$4.333. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$22.14 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Apex Biotechnology's average Cyclically Adjusted Revenue Growth Rate was 0.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Apex Biotechnology was 3.40% per year. The lowest was 0.50% per year. And the median was 2.50% per year.

As of today (2026-07-26), Apex Biotechnology's current stock price is NT$32.05. Apex Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$22.14. Apex Biotechnology's Cyclically Adjusted PS Ratio of today is 1.45.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Apex Biotechnology was 1.83. The lowest was 0.95. And the median was 1.28.


Apex Biotechnology  (TPE:1733) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Apex Biotechnology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32.05/22.14
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Apex Biotechnology was 1.83. The lowest was 0.95. And the median was 1.28.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Apex Biotechnology Cyclically Adjusted Revenue per Share Related Terms


Apex Biotechnology Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Cyclically Adjusted Revenue per Share Chart

Apex Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.84 21.78 21.87 22.05 22.14

Apex Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.05 22.29 22.44 22.37 22.14

TPE:1733 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Apex Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Cyclically Adjusted PS Ratio falls into.


TPE:1733
80GF Score
Apex Biotechnology Corp TPE:1733
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apex Biotechnology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Apex Biotechnology's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=4.333/324.0540*324.0540
=4.333

Current CPI (Dec. 2025) = 324.0540.

Apex Biotechnology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 4.479 238.132 6.095
201606 4.857 241.018 6.530
201609 3.213 241.428 4.313
201612 3.700 241.432 4.966
201703 4.262 243.801 5.665
201706 4.004 244.955 5.297
201709 4.762 246.819 6.252
201712 3.574 246.524 4.698
201803 4.706 249.554 6.111
201806 4.555 251.989 5.858
201809 4.968 252.439 6.377
201812 4.622 251.233 5.962
201903 4.659 254.202 5.939
201906 5.040 256.143 6.376
201909 4.765 256.759 6.014
201912 5.859 256.974 7.388
202003 4.521 258.115 5.676
202006 4.943 257.797 6.213
202009 4.631 260.280 5.766
202012 4.005 260.474 4.983
202103 5.096 264.877 6.235
202106 4.528 271.696 5.401
202109 5.091 274.310 6.014
202112 5.548 278.802 6.448
202203 5.187 287.504 5.846
202206 6.068 296.311 6.636
202209 6.055 296.808 6.611
202212 5.040 296.797 5.503
202303 4.342 301.836 4.662
202306 4.170 305.109 4.429
202309 4.140 307.789 4.359
202312 4.104 306.746 4.336
202403 4.493 312.332 4.662
202406 4.334 314.175 4.470
202409 5.084 315.301 5.225
202412 4.510 315.605 4.631
202503 5.566 319.799 5.640
202506 5.162 322.561 5.186
202509 4.345 324.800 4.335
202512 4.333 324.054 4.333

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$22.14 mean?
Apex Biotechnology (TPE:1733) has a Cyclically Adjusted Revenue per Share of NT$22.14 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Apex Biotechnology and its competitors.
Is Apex Biotechnology's Cyclically Adjusted Revenue per Share too high?
Apex Biotechnology's current Cyclically Adjusted Revenue per Share is NT$22.14. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Apex Biotechnology's Cyclically Adjusted Revenue per Share of NT$22.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Cyclically Adjusted Revenue per Share is NT$22.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.01, compared to a current price of NT$32.05 — trading 6.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$22.14. Apex Biotechnology's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Cyclically Adjusted Revenue per Share is NT$22.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued. The current stock price of NT$32.05 is trading 6.8% above its estimated GF Value™ of NT$30.01. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

  • Cyclically Adjusted Revenue per Share: NT$22.14
  • GF Value™: NT$30.01 vs. price of NT$32.05 (6.8% above fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apex Biotechnology Business Description

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score

Get the complete analysis for TPE:1733

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.05
Price
NT$30.01
GF Value